Sildenafil for COPD: A randomized crossover trial

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 3, 2012, Pages 211-212

  Bull, Todd ^a   Badesch, David B ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL;

6 MINUTE WALK TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; EDITORIAL; EXERCISE TOLERANCE; HUMAN; LUNG FUNCTION TEST; MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE;

EXERCISE TEST; FEMALE; HUMANS; MALE; OXYGEN CONSUMPTION; PIPERAZINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PURINES; SULFONES; VASODILATOR AGENTS;

EID: 84862102903     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.683966     Document Type: Editorial

References (17)

1. Kessler, R., M. Faller, E. Weitzenblum, A. Chaouat, A. Aykut, A. Ducolone, M. Ehrhart, and M. Oswald-Mammosser. 2001. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am.J Respir. Crit Care Med. 164:219-224.
2. Kessler, R., M. Faller, G. Fourgaut, B. Mennecier, and E. Weitzenblum. 1999. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am.J Respir.Crit Care Med. 159:158-164.
3. Traver, G. A., M. G. Cline, and B. Burrows. 1979. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am.Rev.Respir.Dis 119:895-902.
4. Weitzenblum, E., C. Hirth, A. Ducolone, R. Mirhom, J. Rasaholinjanahary, and M. Ehrhart. 1981. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Th orax 36:752-758.
5. Th abut, G., G. Dauriat, J. B. Stern, D. Logeart, A. Levy, R. Marrash-Chahla, and H. Mal. 2005. Pulmonary hemodynamics in advanced copd candidates for lung volume reduction surgery or lung transplantation. Chest 127:1531-1536.
6. Cuttica, M. J., R. Kalhan, O. A. Shlobin, S. Ahmad, M. Gladwin, R. F. Machado, S. D. Barnett, and S. D. Nathan. 2010. Categorization and impact of pulmonary hypertension in patients with advanced copd. Respir.Med.
7. Scharf, S. M., M. Iqbal, C. Keller, G. Criner, S. Lee, and H. E. Fessler. 2002. Hemodynamic characterization of patients with severe emphysema. Am.J Respir.Crit Care Med. 166:314-322.
8. Oswald-Mammosser, M., E. Weitzenblum, E. Quoix, G. Moser, A. Chaouat, C. Charpentier, and R. Kessler. 1995. Prognostic factors in copd patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 107: 1193-1198.
9. Chaouat, A., A. S. Bugnet, N. Kadaoui, R. Schott, I. Enache, A. Ducolone, M. Ehrhart, R. Kessler, and E. Weitzenblum. 2005. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am.J Respir.Crit Care Med. 172:189-194.
10. McLaughlin, V. V., S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al. 2009. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am.Coll. Cardiol. 53:1573-1619.
11. Badesch, D. B., S. H. Abman, G. Simonneau, L. J. Rubin, and V. V. McLaughlin. 2007. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 131:1917-1928.
12. Humbert, M. and V. V. McLaughlin. 2009. The 4th World Symposium on Pulmonary Hypertension. Introduction. J Am.Coll.Cardiol. 54:S1-S2.
13. Galie, N., H. A. Ghofrani, A. Torbicki, R. J. Barst, L. J. Rubin, D. Badesch, T. Fleming, T. Parpia, G. Burgess, A. Branzi, et al. 2005. Sildenafi l citrate therapy for pulmonary arterial hypertension. N.Engl.J Med. 353:2148-2157.
14. Blanco, I., E. Gimeno, P. A. Munoz, S. Pizarro, C. Gistau, R. Rodriguez-Roisin, J. Roca, and J. A. Barbera. 2010. Hemodynamic and gas exchange eff ects of sildenafi l in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am.J Respir.Crit Care Med. 181: 270-278.
15. Stolz, D., H. Rasch, A. Linka, M. Di Valentino, A. Meyer, M. Brutsche, and M. Tamm. 2008. A randomised, controlled trial of bosentan in severe copd. Eur.Respir.J 32:619-628.
16. Collard, H. R., K. J. Anstrom, M. I. Schwarz, and D. A. Zisman. 2007. Sildenafi l improves walk distance in idiopathic pulmonary fi brosis. Chest 131:897-899.
17. Zisman, D. A., M. Schwarz, K. J. Anstrom, H. R. Collard, K. R. Flaherty, and G. W. Hunninghake. 2010. A controlled trial of sildenafi l in advanced idiopathic pulmonary fi brosis. N.Engl.J.Med. 363:620-628.